Successful mandibular reconstruction using a BMP bioimplant.
A bone morphogenetic protein bioimplant was used for primary reconstruction of a 6-cm mandibular discontinuity defect, after a segmental resection of an ameloblastoma. Radiographic evidence of new bone induction was seen at 3 and 9 months, postoperatively. A biopsy was taken at 9 months demonstrated viable new bone formation at the bioimplant site. This is the first reported case using a bone morphogenetic protein bioimplant in a human, followed by histological confirmation of new bone.
Moghadam
H G
HG
University of Toronto, 124 Edward Street, Toronto, Ontario M5B 1G6, Canada.
Urist
M R
MR
Sandor
G K
GK
Clokie
C M
CM
D000328:Adult; D000564:Ameloblastoma / Q000601:surgery*; D001706:Biopsy; D001857:Bone Matrix / Q000637:transplantation*; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D001860:Bone Plates; D001863:Bone Screws; D018786:Bone Substitutes / Q000627:therapeutic use*; D004337:Drug Carriers; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D008297:Male; D008334:Mandible / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D008339:Mandibular Neoplasms / Q000601:surgery*; D010011:Osteocytes / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010027:Osteotomy; D020442:Poloxamer; D011859:Radiography; D014184:Transplantation, Homologous
D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D004337:Drug Carriers; D005782:Gels; D020442:Poloxamer